XML 12 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues:    
Total revenues $ 235 $ 0
Revenue, Product and Service [Extensible Enumeration] License and Collaboration Revenues [Member] License and Collaboration Revenues [Member]
Operating expenses:    
Research and development $ 13,364 $ 9,379
General and administrative 3,507 3,408
Total operating expenses 16,871 12,787
Loss from operations (16,636) (12,787)
Total other income (expense), net 1,149 835
Consolidated net loss (15,487) (11,952)
Net (gain) loss attributable to noncontrolling interest in Pangu BioPharma Limited (4) 1
Net loss attributable to aTyr Pharma, Inc. $ (15,491) $ (11,951)
Net loss per share - basic $ (0.23) $ (0.29)
Net loss per share - diluted $ (0.23) $ (0.29)
Shares used in computing net loss per share, basic 66,080,593 41,897,706
Shares used in computing net loss per share, diluted 66,080,593 41,897,706